Screening for prostate cancer: Who and how often?

Journal of Family Practice

Volumn 54, Issue 7, 2005, Pages 586-596

  Schwartz, Kendra ^a,b   Deschere, Bruce ^a   Xu, Jinping ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANTIGEN DETECTION; CANCER MORTALITY; CANCER SCREENING; CANCER SURVIVAL; CANCER THERAPY; DIAGNOSTIC ACCURACY; DIGITAL RECTAL EXAMINATION; DOCTOR PATIENT RELATION; GLEASON SCORE; HUMAN; INFORMED CONSENT; LIFE EXPECTANCY; MALE; MEDICAL INFORMATICS; METASTASIS; PATIENT COUNSELING; PATIENT SELECTION; PRACTICE GUIDELINE; PROSTATE CANCER; REVIEW; RISK BENEFIT ANALYSIS;

BIOPSY; HUMANS; MALE; MASS SCREENING; PALPATION; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECTUM;

EID: 22044453699     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. American Academy of Family Physicians. Summary of recommendation for periodic health examinations. August 2002. Available at: www.aafp.org/PreBuilt/ PHERev5.30802.pdf. Accessed on June 10, 2005.
2. US Preventive Services Task Force. Screening for Prostate Cancer. 2002. Available at: www.ahrq.gov/ clinic/uspstf/uspsprca.htm. Accessed on June 10, 2005.
3. American College of Physicians. Screening for prostate cancer. Position paper. Clinical Guideline: Part III. Ann Intern Med 1997; 126:480-484.
4. Harris R, Lohr K, Beck R, Fink K, Godley P, Bunton A. Screening for prostate cancer. Systematic Evidence Review for AHRQ. Available at: www.ahrq.gov/ uspstfix.htm. Accessed on June 10, 2005.
5. American Cancer Society. Cancer statistics 2005. CA Cancer J Clin 2005; 55:10-30.
6. Ries L, Eisner M, Kosary C, et al. SEER Cancer Statistics Review, 1975-2000. Bethesda, Md: National Cancer Institute; 2003. Available at seer.cancer.gov/ csr/1975_2002/. Accessed on June 10, 2005.
7. DevCan: Probability of dying of cancer [computer program]. Version 5.1. Bethesda, Md: National Cancer Instititute; 2003. Available at: srab.cancer.gov/devcan/. Accessed on June 10, 2005.
8. Neal DE, Leung HY, Powell PH, Hamdy FC, Donovan JL. Unanswered questions in screening for prostate cancer. Eur J Cancer 2000; 36:1316-1321.
9. US Preventive Services Task Force. Guide to Clinical Preventive Services. 2nd ed. Alexandria, Va: International Medical Publishing; 1996.
10. Kabalin J, McNeal J, Price H, Freina F, Stamey T. Unsuspected adenocarcinoma of the prostate in patients undergooing cystoprostatectomy for other causes: incidence, histology and morphometric observations. J Urol 1989; 141:1091-1094.
11. Montie J, Wood DJ, Pontes J, Boyett J, Levin H. Adenocarcinoma of the prostate in cystoprostatectomy specimens removed for bladder cancer. Cancer 1989; 63:381-385.
12. Bunting PS. Screening for prostate cancer with prostate-specific antigen: beware the biases. Clin Chim Acta 2002; 315:71-97.
13. Gronberg H. Prostate cancer epidemiology. Lancet 2003; 361:859-864.
14. Harris R, Lohr KN. Screening for prostate cancer: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 137:917-929.
15. American Cancer Society. ACS Cancer Detection Guidelines. Available at: www.cancer.org/docroot/PED/ content/ PED_2_3X_ACS_Cancer_Detection_Guidelines _36.asp. Accessed June 10, 2005.
16. Smith D, Catalona W. Interexaminer variability of digital rectal examination in detecting prostate cancer. Urology 1995; 45:70-74.
17. Kishor M, Cable G. Meta-analysis of prostate-specific antigen and digital rectal examination as screening tests for prostate carcinoma. J Am Board Fam Pract 2003; 16:95-101.
18. Hoogendam A, Buntix F, deVet HCW. The diagnostic value of digital rectal examination in primary care screening for prostate cancer: a meta-analysis. Fam Pract 1999; 16:621-626.
19. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995; 273:289-294.
20. Hakama M, Stenman UH, Aromaa A, Leinonen J, Hakulinen T, Knekt I. Validity of the prostate specific antigen test for prostate cancer screening: followup study with a bank of 21,000 sera in Finland. J Urol 2001; 166:2189-2191.
21. Humphrey L, Helfand M, Chan B, Woolf S. Breast cancer screening: summary of the evidence. Ann Intern Med 2002; 137:344-346.
22. Thompson I, Pauler D, Goodman R et al. Prevalence of prostate cancer among men with a prostate-specific antigen level <4 ng per milliliter. N Engl J Med 2004; 350:2239-2246.
23. Collins MM, Ransohoff D, MJ Barry. Early detection of prostate cancer-serendipity strikes again. JAMA 1997; 278:1516-1519.
24. Eastham J, Riedel E, Scardino P, et al. Variation of serum prostate-specific antigen levels. An evaluation of year-to-year fluctuations. JAMA 2003; 289:2695-2700.
25. Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002; 94:981-990.
26. Zappa M, Ciatto S, Bonardi R, Mazzotta A. Overdiagnosis of prostate carcinoma by screening: an estimate based on the results of the Florence Screening Pilot Study. Ann Oncol 1998; 9:1297-1300.
27. Draisma G, Boer R, Otto S, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European randomized study of screening for prostate cancer. J Natl Cancer Inst 2003; 95:868-878.
28. Auvin A, Maattanen L, Stenman UH, et al. Lead-time in prostate cancer screening (Finland). Cancer Causes Control 2002; 13:279-285.
29. Gleason D, Mellinger G, Group at VACUR. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974; 111:58-64.
30. Albertson PC, Hanley JA, Fine J. 20-Year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005; 293:2095-2101.
31. Schwartz K, Grignon D, Sakr W, Wood DJ. Prostate cancer histologic trends in the metropolitan Detroit are, 1982 to 1996. Urology 1999; 53:769-774.
32. Smith D, Catalona W. The nature of prostate cancer detected through prostate specific antigen based screening. J Urol 1994; 152:1732-1736.
33. Hoedemaeker RF, van der Kwast T, Boer R, et al. Pathological features of prostate cancer found at population-based screening with a four-year interval. J Natl Cancer Inst 2001; 93:1153-1158.
34. Chu KC, Tarone RE, Freeman HP. Trends in prostate cancer mortality among black men and white men in the United States. Cancer 2003; 97:1507-1516.
35. National Cancer Institute of Canada. Canadian cancer statistics 2001. Toronto: National Cancer Institute of Canada; 2001. Available at: www.ncic.cancer.ca. Accessed June 10, 2005.
36. Coory M, Baade P. Mortality from prostate cancer is decreasing. Med J Aust 2002; 176:345-345.
37. Majeed A, Babb P, Jones J, Quinn M. Trends in prostate cancer incidence, mortality and survival in England and Wales, 1971-1998. BJU Int 2000; 85:1058-1062.
38. Oliver S, Gunnell D, Donovan J. Comparison of trends in prostate-cancer mortality in England and Wales and the USA. Lancet 2000; 355:1788-1789.
39. Lu-Yao G, Albertsen PC, Stanford JL, Stukel TA, Walker-Corkery ES, Barry MJ. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ 2002; 325:740.
40. Coldman A, Phillips N, Pickles T. Trends in prostate cancer incidence and mortality: an analysis of mortality change by screening intensity. CMAJ 2003; 168:31-35.
41. Feuer EJ, Merrill RM, Hankey BF. Cancer surveillance series: interpreting trends in prostate cancer-part II: Cause of death misclassification and the recent rise and fall in prostate cancer mortality. J Natl Cancer Inst 1999; 91:1025-1032.
42. Frankel S, Smith GD, Donovan J, Neal D. Screening for prostate cancer. Lancet 2003; 361:1122-1128.
43. Partin MR, Wilt TJ. Informing patients about prostate cancer screening: identifying and meeting the challenges while the evidence remains uncertain. Am J Med 2002; 113:691-693.
44. McFall SL, Hamm RM. Interpretation of prostate cancer screening events and outcomes: a focus group study. Patient Educ Courts 2003; 49:207-218.
45. Litwin MS, Hays RD, Fink A, et al. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA 1995; 273:129-135.
46. Penson DF, Litwin MS. Quality of life after treatment for prostate cancer. Curr Urol Rep 2003; 4:185-195.
47. Lubeck DP, Litwin MS, Henning JM, Stoddard ML, Flanders SC, Carroll PR. Changes in the health-related quality of life in the first year after treatment for prostate cancer: results from CaPSURE. Urology 1999; 53:180-186.
48. Bacon C, Giovannucci E, Testa M, Kawachi I. The impact of cancer treatment on quality of life outcomes for patients with localized prostate cancer. J Urol 2001; 166:1804-1810.
49. Makinen T, Auvinen A, Hakama M, Stenman UH, Tammela TL. Acceptability and complications of prostate biopsy in population-based PSA screening versus routine clinical practice: a prospective, controlled study. Urology 2002; 60:846-850.
50. Fowler FJ, Jr., Barry MJ, Lu-Yao G, Roman A, Wasson J, Wennberg JE. Patient-reported complications and follow-up treatment after radical prostatectomy. The National Medicare Experience: 1988-1990 (updated June 1993). Urology 1993; 42:622-629.
51. Schwartz K, Bunner S, Bearer R, Severson RK. Complications from treatment for prostate carcinoma among men in the Detroit area. Cancer 2002; 95:82-89.
52. Potosky AL, Legler J, Albertsen PC, et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst 2000; 92:1582-1592.
53. Sebesta M, Cespedes RD, Luhman E, Optenberg S, Thompson IM. Questionnaire-based outcomes of urinary incontinence and satisfaction rates after radical prostatectomy in a national study population. Urology 2002;60:1055-1058.
54. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005; 352:1977-1184.
55. Labrie F, Candas B, Dupont A, et al. Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate 1999; 38:83-91.
56. Alexander FE, Prescott RJ. Reply to Labrie et al. Results of the mortality analysis of the Quebec randomized controlled trial (RCT). Prostate 1999; 40:135-137.
57. Prorok P, Andriole G, Bresalier R, et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials 2000; 21:2735-3095.
58. Standaert B, Denis L. The European Randomized Study of Screening for Prostate Cancer: an update. Cancer 1997; 80:1830-1834.
59. Wilt TJ, Brawer M. The Prostate Cancer Intervention Versus Observation Trial: a randomized trial comparing radical prostatectomy versus expectant management for the treatment of clinically localized prostate cancer. J Urol 1994; 152:1910-1914.
60. Schapira M, VanRuiswyk J. The effect of an illustrated pamphlet decision-aid on the use of prostate cancer screening tests. J Fam Pract 2000; 49:418-424.
61. Davison B, Kirk P, Degner L, Hassard T. Information and patient participation in screening for prostate cancer. Patient Educ Couns 1999; 37:255-263.
62. Merenstein D. Winners and losers. JAMA 2004; 291:15-16.
63. Horninger W, Berger A, Pelzer A, et al. Screening for prostate cancer: updated experience from the Tyrol study. Current Urol Reports 2004; 5:220-225.
64. Raaijmakers R, Kirkels WJ, Roobol MJ, Wildhagen MF, Schrder FH. Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. Urology 2002; 60:826-830.
65. Fowler F, Barry MJ, Lu-Yao G, Wasson J, Bin L. Outcomes of external beam radiation therapy for prostate cancer: a study of Medicare beneficiaries in three Surveillance, Epidemiology, and End Results areas. J Clin Oncol 1996; 14:2258-2265.
66. Hollenbeck BK, Dunn RL, Wei JT, Sandler HM, Sanda MG. Sexual health recovery after prostatectomy, external radiation, or brachytherapy for early stage prostate cancer. Curr Urol Rep 2004; 5:212-219.
67. Potosky AL, Knopf K, Clegg LX, et al. Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. J Clin Oncol 2001; 19:3750-3757.
68. Lee R, Penson DF. Treatment outcomes in localized prostate cancer: a patient-oriented approach. Semin Urol Oncol 2002; 20:63-73.
69. Stanford JL, Feng Z, Hamilton AS, et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA 2000; 283:354-360.
70. Robinson JW, Moritz S, Fung T. Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma. Int J Radiat Oncol Biol Phys 2002; 54:1063-1068.
71. Coley CM, Barry MJ, Fleming C, Fahs MC, Mulley AG. Early detection of prostate cancer. Part II: Estimating the risks, benefits, and costs. American College of Physicians. Ann Intern Med 1997; 126:468-479.